Esperion Therapeutics Inc. (NASDAQ:ESPR) has received an average rating of “Hold” from the fourteen analysts that are covering the firm. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $25.35.

Several brokerages recently issued reports on ESPR. Barclays PLC set a $13.00 price objective on Esperion Therapeutics and gave the stock a “hold” rating in a report on Wednesday, August 31st. Zacks Investment Research lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 30th. Vetr lowered Esperion Therapeutics from a “strong-buy” rating to a “buy” rating and set a $12.60 price objective for the company. in a report on Tuesday, August 23rd. JPMorgan Chase & Co. set a $15.00 price objective on Esperion Therapeutics and gave the stock a “hold” rating in a report on Friday, August 5th. Finally, Credit Suisse Group AG reiterated a “sell” rating and set a $10.00 price objective on shares of Esperion Therapeutics in a report on Wednesday, July 6th.

In other news, Director Mark E. Mcgovern bought 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 6th. The shares were acquired at an average cost of $10.00 per share, with a total value of $50,000.00. Following the completion of the transaction, the director now directly owns 600 shares in the company, valued at $6,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 35.40% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the company. Quantitative Investment Management LLC purchased a new stake in Esperion Therapeutics during the second quarter worth $111,000. Advisor Group Inc. purchased a new stake in Esperion Therapeutics during the second quarter worth $140,000. Stifel Financial Corp increased its stake in Esperion Therapeutics by 10.6% in the second quarter. Stifel Financial Corp now owns 15,017 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 1,438 shares during the period. Rhumbline Advisers increased its stake in Esperion Therapeutics by 27.0% in the second quarter. Rhumbline Advisers now owns 17,186 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 3,657 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Esperion Therapeutics during the first quarter worth $313,000. 65.22% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics (NASDAQ:ESPR) opened at 11.22 on Wednesday. The company has a 50 day moving average price of $10.96 and a 200 day moving average price of $14.40. Esperion Therapeutics has a 1-year low of $9.58 and a 1-year high of $49.36. The firm’s market cap is $253.01 million.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.78) by $0.16. During the same period in the previous year, the business earned ($0.55) EPS. On average, equities research analysts forecast that Esperion Therapeutics will post ($3.37) earnings per share for the current year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

5 Day Chart for NASDAQ:ESPR

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.